Abstract
Insulin-like growth factor-binding protein 7 (IGFBP7) is a selective biomarker of glioblastoma (GBM) vessels, strongly expressed in tumor endothelial cells and vascular basement membrane. IGFBP7 gene regulation and its potential role in tumor angiogenesis remain unclear. Mechanisms of IGFBP7 induction and its angiogenic capacity were examined in human brain endothelial cells (HBECs) exposed to tumor-like conditions. HBEC treated with GBM cell (U87MG)-conditioned media (-CM) exhibited fourfold upregulation of IGFBP7 mRNA and protein compared to control cells. IGFBP7 gene regulation in HBEC was methylation independent. U87MG-CM analysed by enzyme-linked immunosorbent assay contained ∼5 pM transforming growth factor (TGF)-β1, a concentration sufficient to stimulate IGFBP7 in HBEC to similar levels as U87MG-CM. Both pan-TGF-β-neutralizing antibody (1D11) and the TGF-β1 receptor (activin receptor-like kinase 5, ALK5) antagonist, SB431542, blocked U87MG-CM-induced IGFBP7 expression in HBEC, indicating that TGF-β1 is an important tumor-secreted effector capable of IGFBP7 induction in endothelial cells. HBEC exposed to either U87MG-CM or IGFBP7 protein exhibited increased capillary-like tube (CLT) formation in Matrigel. Both TGF-β1- and U87MG-CM-induced Smad-2 phosphorylation and U87MG-CM-induced CLT formation in HBEC were inhibited by the ALK5 antagonist, SB431542. These data suggest that proangiogenic IGFBP7 may be induced in brain endothelial cells by TGF-βs secreted by GBM, most likely through TGF-β1/ALK5/Smad-2 pathway.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ahmed S, Jin X, Yagi M, Yasuda C, Sato Y, Higashi S et al. (2006). Identification of membrane-bound serine proteinase matriptase as processing enzyme of insulin-like growth factor binding protein-related protein-1 (IGFBP-rP1/angiomodulin/mac25). FEBS J 273: 615–627.
Akaogi K, Okabe Y, Funahashi K, Yoshitake Y, Nishikawa K, Yasumitsu H et al. (1994). Cell adhesion activity of a 30-kDa major secreted protein from human bladder carcinoma cells. Biochem Biophys Res Commun 198: 1046–1053.
Akaogi K, Okabe Y, Sato J, Nagashima Y, Yasumitsu H, Sugahara K et al. (1996). Specific accumulation of tumor-derived adhesion factor in tumor blood vessels and in capillary tube-like structures of cultured vascular endothelial cells. Proc Natl Acad Sci USA 93: 8384–8389.
Beaty RM, Edwards JB, Boon K, Siu IM, Conway JE, Riggins GJ . (2007). PLXDC1 (TEM7) is identified in a genome-wide expression screen of glioblastoma endothelium. J Neurooncol 81: 241–248.
Blanchette F, Rivard N, Rudd P, Grondin F, Attisano L, Dubois CM . (2001). Cross-talk between the p42/p44 MAP kinase and Smad pathways in transforming growth factor beta 1-induced furin gene transactivation. J Biol Chem 276: 33986–33994.
Burger AM, Zhang X, Li H, Ostrowski JL, Beatty B, Venanzoni M et al. (1998). Down-regulation of T1A12/mac25, a novel insulin-like growth factor binding protein related gene, is associated with disease progression in breast carcinomas. Oncogene 16: 2459–2467.
Chen Y, Pacyna-Gengelbach M, Ye F, Knosel T, Lund P, Deutschmann N et al. (2007). Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) has potential tumour-suppressive activity in human lung cancer. J Pathol 211: 431–438.
Chen YG, Massague J . (1999). Smad1 recognition and activation by the ALK1 group of transforming growth factor-beta family receptors. J Biol Chem 274: 3672–3677.
Constam DB, Philipp J, Malipiero UV, ten Dijke P, Schachner M, Fontana A . (1992). Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J Immunol 148: 1404–1410.
Dai C, Holland EC . (2001). Glioma models. Biochim Biophys Acta 1551: M19–M27.
Davies DC . (2002). Blood–brain barrier breakdown in septic encephalopathy and brain tumours. J Anat 200: 639–646.
de Caestecker M . (2004). The transforming growth factor-beta superfamily of receptors. Cytokine Growth Factor Rev 15: 1–11.
Deb-Rinker P, Ly D, Jezierski A, Sikorska M, Walker PR . (2005). Sequential DNA methylation of the Nanog and Oct-4 upstream regions in human NT2 cells during neuronal differentiation. J Biol Chem 280: 6257–6260.
Derynck R, Zhang Y, Feng XH . (1998). Smads: transcriptional activators of TGF-beta responses. Cell 95: 737–740.
Dinda AK, Sarkar C, Roy S, Kharbanda K, Mathur M, Khosla AK et al. (1993). A transmission and scanning electron microscopic study of tumoral and peritumoral microblood vessels in human gliomas. J Neurooncol 16: 149–158.
Durocher Y, Perret S, Kamen A . (2002). High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 30: E9.
Engel ME, McDonnell MA, Law BK, Moses HL . (1999). Interdependent SMAD and JNK signaling in transforming growth factor-beta-mediated transcription. J Biol Chem 274: 37413–37420.
Goumans MJ, Lebrin F, Valdimarsdottir G . (2003). Controlling the angiogenic switch: a balance between two distinct TGF-b receptor signaling pathways. Trends Cardiovasc Med 13: 301–307.
Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P . (2002). Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J 21: 1743–1753.
Hata Y, Clermont A, Yamauchi T, Pierce EA, Suzuma I, Kagokawa H et al. (2000). Retinal expression, regulation, and functional bioactivity of prostacyclin-stimulating factor. J Clin Invest 106: 541–550.
Hirano A, Matsui T . (1975). Vascular structures in brain tumors. Hum Pathol 6: 611–621.
Hwa V, Oh Y, Rosenfeld RG . (1999). The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 20: 761–787.
Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD et al. (2002). SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 62: 65–74.
Keeton MR, Curriden SA, van Zonneveld AJ, Loskutoff DJ . (1991). Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor beta. J Biol Chem 266: 23048–23052.
Kishibe J, Yamada S, Okada Y, Sato J, Ito A, Miyazaki K et al. (2000). Structural requirements of heparan sulfate for the binding to the tumor-derived adhesion factor/angiomodulin that induces cord-like structures to ECV-304 human carcinoma cells. J Biol Chem 275: 15321–15329.
Kleihues P, Soylemezoglu F, Schauble B, Scheithauer BW, Burger PC . (1995). Histopathology, classification, and grading of gliomas. Glia 15: 211–221.
Kniesel U, Wolburg H . (2000). Tight junctions of the blood–brain barrier. Cell Mol Neurobiol 20: 57–76.
Komatsu S, Okazaki Y, Tateno M, Kawai J, Konno H, Kusakabe M et al. (2000). Methylation and downregulated expression of mac25/insulin-like growth factor binding protein-7 is associated with liver tumorigenesis in SV40T/t antigen transgenic mice, screened by restriction landmark genomic scanning for methylation (RLGS-M). Biochem Biophys Res Commun 267: 109–117.
Kwak HJ, Park MJ, Cho H, Park CM, Moon SI, Lee HC et al. (2006). Transforming growth factor-beta1 induces tissue inhibitor of metalloproteinase-1 expression via activation of extracellular signal-regulated kinase and Sp1 in human fibrosarcoma cells. Mol Cancer Res 4: 209–220.
Lebrin F, Deckers M, Bertolino P, Ten Dijke P . (2005). TGF-beta receptor function in the endothelium. Cardiovasc Res 65: 599–608.
Lin J, Lai M, Huang Q, Ma Y, Cui J, Ruan W . (2007). Methylation patterns of IGFBP7 in colon cancer cell lines are associated with levels of gene expression. J Pathol 212: 83–90.
Long DM . (1970). Capillary ultrastructure and the blood–brain barrier in human malignant brain tumors. J Neurosurg 32: 127–144.
Louis DN . (2006). Molecular pathology of malignant gliomas. Annu Rev Pathol 1: 97–117.
Madden SL, Cook BP, Nacht M, Weber WD, Callahan MR, Jiang Y et al. (2004). Vascular gene expression in nonneoplastic and malignant brain. Am J Pathol 165: 601–608.
Massague J . (1998). TGF-beta signal transduction. Annu Rev Biochem 67: 753–791.
Miller SA, Dykes DD, Polesky HF . (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215.
Moreno MJ, Ball M, Andrade MF, McDermid A, Stanimirovic DB . (2006). Insulin-like growth factor binding protein-4 (IGFBP-4) is a novel anti-angiogenic and anti-tumorigenic mediator secreted by dibutyryl cyclic AMP (dB-cAMP)-differentiated glioblastoma cells. Glia 53: 845–857.
Murphy M, Pykett MJ, Harnish P, Zang KD, George DL . (1993). Identification and characterization of genes differentially expressed in meningiomas. Cell Growth Differ 4: 715–722.
Mutaguchi K, Yasumoto H, Mita K, Matsubara A, Shiina H, Igawa M et al. (2003). Restoration of insulin-like growth factor binding protein-related protein 1 has a tumor-suppressive activity through induction of apoptosis in human prostate cancer. Cancer Res 63: 7717–7723.
Nagakubo D, Murai T, Tanaka T, Usui T, Matsumoto M, Sekiguchi K et al. (2003). A high endothelial venule secretory protein, mac25/angiomodulin, interacts with multiple high endothelial venule-associated molecules including chemokines. J Immunol 171: 553–561.
Oh Y, Nagalla SR, Yamanaka Y, Kim HS, Wilson E, Rosenfeld RG . (1996). Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7. Recombinant human mac25 protein specifically binds IGF-I and -II. J Biol Chem 271: 30322–30325.
Oldendorf WH, Cornford ME, Brown WJ . (1977). The large apparent work capability of the blood–brain barrier: a study of the mitochondrial content of capillary endothelial cells in brain and other tissues of the rat. Ann Neurol 1: 409–417.
Olofsson A, Miyazono K, Kanzaki T, Colosetti P, Engstrom U, Heldin CH . (1992). Transforming growth factor-beta 1, -beta 2, and -beta 3 secreted by a human glioblastoma cell line. Identification of small and different forms of large latent complexes. J Biol Chem 267: 19482–19488.
Pen A, Moreno MJ, Martin J, Stanimirovic DB . (2007). Molecular markers of extracellular matrix remodeling in glioblastoma vessels: microarray study of laser-captured glioblastoma vessels. Glia 55: 559–572.
Pepper MS . (1997). Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev 8: 21–43.
Poncelet AC, Schnaper HW . (1998). Regulation of human mesangial cell collagen expression by transforming growth factor-beta1. Am J Physiol 275: F458–F466.
Ramsauer M, D'Amore PA . (2007). Contextual role for angiopoietins and TGF-beta1 in blood vessel stabilization. J Cell Sci 120: 1810–1817.
Reed MJ, Vernon RB, Abrass IB, Sage EH . (1994). TGF-beta 1 induces the expression of type I collagen and SPARC, and enhances contraction of collagen gels, by fibroblasts from young and aged donors. J Cell Physiol 158: 169–179.
Ruan W, Xu E, Xu F, Ma Y, Deng H, Huang Q et al. (2007). IGFBP7 plays a potential tumor suppressor role in colorectal carcinogenesis. Cancer Biol Ther 6: 354–359.
Sato J, Hasegawa S, Akaogi K, Yasumitsu H, Yamada S, Sugahara K et al. (1999). Identification of cell-binding site of angiomodulin (AGM/TAF/Mac25) that interacts with heparan sulfates on cell surface. J Cell Biochem 75: 187–195.
Sprenger CC, Damon SE, Hwa V, Rosenfeld RG, Plymate SR . (1999). Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) is a potential tumor suppressor protein for prostate cancer. Cancer Res 59: 2370–2375.
St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E et al. (2000). Genes expressed in human tumor endothelium. Science 289: 1197–1202.
Stanimirovic D, Morley P, Ball R, Hamel E, Mealing G, Durkin JP . (1996). Angiotensin II-induced fluid phase endocytosis in human cerebromicrovascular endothelial cells is regulated by the inositol-phosphate signaling pathway. J Cell Physiol 169: 455–467.
ten Dijke P, Hansen P, Iwata KK, Pieler C, Foulkes JG . (1988). Identification of another member of the transforming growth factor type beta gene family. Proc Natl Acad Sci USA 85: 4715–4719.
Umeda F, Ono Y, Sekiguchi N, Hashimoto T, Masakado M, Nakamura K et al. (1998). Increased mRNA expression of a novel prostacyclin-stimulating factor in human colon cancer. J Gastroenterol 33: 213–217.
Vajkoczy P, Goldbrunner R, Farhadi M, Vince G, Schilling L, Tonn JC et al. (1999). Glioma cell migration is associated with glioma-induced angiogenesis in vivo. Int J Dev Neurosci 17: 557–563.
Vajkoczy P, Menger MD . (2000). Vascular microenvironment in gliomas. J Neurooncol 50: 99–108.
van Beijnum JR, Dings RP, van der Linden E, Zwaans BM, Ramaekers FC, Mayo KH et al. (2006). Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood 108: 2339–2348.
Vaupel P, Thews O, Kelleher DK, Hoeckel M . (1998). Oxygenation of human tumors: the Mainz experience. Strahlenther Onkol 174 (Suppl 4): 6–12.
Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR . (2008). Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 132: 363–374.
Watabe T, Nishihara A, Mishima K, Yamashita J, Shimizu K, Miyazawa K et al. (2003). TGF-beta receptor kinase inhibitor enhances growth and integrity of embryonic stem cell-derived endothelial cells. J Cell Biol 163: 1303–1311.
Weller M, Malipiero U, Groscurth P, Fontana A . (1995). T cell apoptosis induced by interleukin-2 deprivation or transforming growth factor-beta 2: modulation by the phosphatase inhibitors okadaic acid and calyculin A. Exp Cell Res 221: 395–403.
Wick W, Platten M, Weller M . (2001). Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta. J Neurooncol 53: 177–185.
Wilson HM, Birnbaum RS, Poot M, Quinn LS, Swisshelm K . (2002). Insulin-like growth factor binding protein-related protein 1 inhibits proliferation of MCF-7 breast cancer cells via a senescence-like mechanism. Cell Growth Differ 13: 205–213.
Yakymovych I, Ten Dijke P, Heldin CH, Souchelnytskyi S . (2001). Regulation of Smad signaling by protein kinase C. FASEB J 15: 553–555.
Yamada N, Kato M, Yamashita H, Nister M, Miyazono K, Heldin CH et al. (1995). Enhanced expression of transforming growth factor-beta and its type-I and type-II receptors in human glioblastoma. Int J Cancer 62: 386–392.
Yamauchi T, Umeda F, Masakado M, Isaji M, Mizushima S, Nawata H . (1994). Purification and molecular cloning of prostacyclin-stimulating factor from serum-free conditioned medium of human diploid fibroblast cells. Biochem J 303 (Part 2): 591–598.
Acknowledgements
We thank Gilles St-Laurent for technical assistance for the production of IGFBP7, Mrs Debbie Callaghan for technical assistance in nuclear protein extraction, Dr Anne Lenferink for valuable discussions and Mr Tom Devecseri for image processing.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)
Rights and permissions
About this article
Cite this article
Pen, A., Moreno, M., Durocher, Y. et al. Glioblastoma-secreted factors induce IGFBP7 and angiogenesis by modulating Smad-2-dependent TGF-β signaling. Oncogene 27, 6834–6844 (2008). https://doi.org/10.1038/onc.2008.287
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2008.287
Keywords
This article is cited by
-
Angiogenesis modulated by CD93 and its natural ligands IGFBP7 and MMRN2: a new target to facilitate solid tumor therapy by vasculature normalization
Cancer Cell International (2023)
-
CD93 is Associated with Glioma-related Malignant Processes and Immunosuppressive Cell Infiltration as an Inspiring Biomarker of Survivance
Journal of Molecular Neuroscience (2022)
-
Association of insulin-like growth factor binding protein-7 promoter methylation with esophageal cancer in peripheral blood
Molecular Biology Reports (2022)
-
Prrx1 promotes stemness and angiogenesis via activating TGF-β/smad pathway and upregulating proangiogenic factors in glioma
Cell Death & Disease (2021)
-
MGMT-inhibitor in combination with TGF-βRI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells
Clinical and Translational Oncology (2021)